Protein kinase C-beta inhibitor enzastaurin (LY317615.HCI) enhances radiation control of murine breast cancer in an orthotopic model of bone metastasis - PubMed (original) (raw)

Protein kinase C-beta inhibitor enzastaurin (LY317615.HCI) enhances radiation control of murine breast cancer in an orthotopic model of bone metastasis

Arkadiusz Z Dudek et al. Invest New Drugs. 2008 Feb.

Abstract

Radiation therapy is a widely used treatment for metastatic bone cancer, but the rapid onset of tumor radioresistance is a major problem. We investigated the radiosensitizing effect of enzastaurin, a protein kinase Cbeta (PKCbeta) inhibitor, on bone tumor growth and tumor-related pain. We found that enzastaurin enhanced the effect of ionizing radiation on cultured murine 4T1 breast cancer and murine endothelial cells, suppressing their proliferation and colony formation. Enzastaurin and ionizing radiation also induced caspase-mediated apoptosis of 4T1 cells to a greater degree than radiation alone. Enzastaurin treatment of 4T1 cells blocked the phosphorylation of PKCbeta, as well as Ras and two of its downstream effectors ERK1/2 and RAL-GTP. Using an orthotopic model of bone metastasis, we observed that a combination of enzastaurin and localized radiation treatment reduced tumor blood vessel density, bone destruction and pain compared to single modality treatment. In conclusion, we demonstrate that inhibition of PKCbeta in combination with localized radiation treatment suppresses tumor growth and alleviates pain as compared to radiation-only treatment. We also show that the radiosensitizing effect of enzastaurin is associated with suppression of tumor cell proliferation and tumor-induced angiogenesis possibly through inhibition of the Ras pathway.

PubMed Disclaimer

Cited by

Tumor-induced STAT3 signaling in myeloid cells impairs dendritic cell generation by decreasing PKCβII abundance.
Farren MR, Carlson LM, Netherby CS, Lindner I, Li PK, Gabrilovich DI, Abrams SI, Lee KP. Farren MR, et al. Sci Signal. 2014 Feb 18;7(313):ra16. doi: 10.1126/scisignal.2004656. Sci Signal. 2014. PMID: 24550541 Free PMC article.
Protein kinase Cβ2 inhibition reduces hyperglycemia-induced neural tube defects through suppression of a caspase 8-triggered apoptotic pathway.
Cao Y, Zhao Z, Eckert RL, Reece EA. Cao Y, et al. Am J Obstet Gynecol. 2011 Mar;204(3):226.e1-5. doi: 10.1016/j.ajog.2011.01.013. Am J Obstet Gynecol. 2011. PMID: 21376163 Free PMC article.
Protein kinase Cbeta is an effective target for chemoprevention of colon cancer.
Fields AP, Calcagno SR, Krishna M, Rak S, Leitges M, Murray NR. Fields AP, et al. Cancer Res. 2009 Feb 15;69(4):1643-50. doi: 10.1158/0008-5472.CAN-08-3187. Cancer Res. 2009. PMID: 19221092 Free PMC article.
A RANKL-PKCβ-TFEB signaling cascade is necessary for lysosomal biogenesis in osteoclasts.
Ferron M, Settembre C, Shimazu J, Lacombe J, Kato S, Rawlings DJ, Ballabio A, Karsenty G. Ferron M, et al. Genes Dev. 2013 Apr 15;27(8):955-69. doi: 10.1101/gad.213827.113. Epub 2013 Apr 18. Genes Dev. 2013. PMID: 23599343 Free PMC article.
Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma.
He Y, Li J, Ding N, Wang X, Deng L, Xie Y, Ying Z, Liu W, Ping L, Zhang C, Song Y, Zhu J. He Y, et al. J Exp Clin Cancer Res. 2019 Feb 18;38(1):86. doi: 10.1186/s13046-019-1076-4. J Exp Clin Cancer Res. 2019. PMID: 30777096 Free PMC article.

References

1. Cancer Chemother Pharmacol. 2004 Feb;53(2):133-40 - PubMed
1. Cancer Res. 2002 Dec 15;62(24):7343-9 - PubMed
1. Neuroscience. 2002;113(1):155-66 - PubMed
1. J Cell Biochem. 2005 Nov 1;96(4):682-8 - PubMed
1. Nat Med. 2000 May;6(5):521-8 - PubMed

Protein kinase C-beta inhibitor enzastaurin (LY317615.HCI) enhances radiation control of murine breast cancer in an orthotopic model of bone metastasis - PubMed (original) (raw)